No connection

Search Results

EBS

BEARISH
$8.03 Live
Emergent BioSolutions Inc. · NYSE
Target $12.0 (+49.4%)
$4.71 52W Range $14.06
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 26, 2026
Market cap
$414.71M
P/E
8.63
ROE
10.5%
Profit margin
7.1%
Debt/Equity
1.12
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
EBS presents as a classic value trap, characterized by a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between its Graham Number ($14.48) and Intrinsic Value ($6.51). While the stock appears cheap on a P/E and P/S basis, this is offset by a severe revenue contraction of -23.6% YoY and negative operating margins (-15.20%). The combination of bearish insider sentiment, a 0/100 technical trend, and extreme earnings volatility suggests that the current price is not yet reflecting the full extent of the fundamental decay.

Key Strengths

Strong short-term liquidity with a Current Ratio of 5.01
Low valuation multiples (P/E 8.63, P/S 0.56)
Healthy Gross Margin of 49.44%
Trading below its Graham Number ($14.48)
Positive ROE (10.46%) despite operating losses

Key Risks

Significant revenue decline (-23.6% YoY and -24.04% Q/Q)
Negative operating margins indicating an unsustainable core business model
Bearish insider activity with consistent selling and zero buying
Extreme EPS volatility and unpredictable earnings track record
Severe long-term price erosion (-87.5% over 5 years)
AI Fair Value Estimate
Based on comprehensive analysis
$7.25
-9.7% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
27
Weak
Value
55
Future
15
Past
20
Health
45
Dividend
0
AI Verdict
High Risk / Value Trap
Key drivers: Revenue contraction, Negative operating margins, Bearish technicals, Insider selling
Confidence
90%
Value
55/100

Ref P/E 8.63, PEG 0.38, Graham Number $14.48

Positives
  • Low P/E
  • P/B below 1.0
  • Low P/S
Watchpoints
  • Intrinsic value ($6.51) is below current price
  • Low PEG ratio is misleading due to negative growth
Future
15/100

Ref Revenue Growth -23.60%

Positives
  • Low forward P/E suggests potential for recovery if earnings stabilize
Watchpoints
  • Revenue growth is sharply negative
  • Q/Q earnings growth is -140.6%
Past
20/100

Ref 5Y Change -87.5%

Positives
  • Recent 1Y recovery (+49.5%)
Watchpoints
  • Catastrophic 5Y performance (-87.5%)
  • Highly inconsistent earnings surprises
Health
45/100

Ref Piotroski F-Score 4/9

Positives
  • Very high Current Ratio (5.01)
  • Piotroski F-Score 4/9 (Stable)
Watchpoints
  • Negative operating margin
  • Debt/Equity ratio of 1.12
Dividend
0/100

Ref Dividend Yield N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$8.03
Analyst Target
$12.0
Upside/Downside
+49.4%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for EBS and closest competitors.

Updated 2026-04-24
EBS
Emergent BioSolutions Inc.
Primary
5Y
-87.5%
3Y
-15.3%
1Y
+49.5%
6M
-17.6%
1M
-2.2%
1W
-8.8%
OVI
Ovid Therapeutics Inc.
Peer
5Y
-27.0%
3Y
-11.8%
1Y
+865.0%
6M
+67.3%
1M
+41.5%
1W
+6.2%
AGL
agilon health, inc.
Peer
5Y
-96.8%
3Y
-95.0%
1Y
-73.1%
6M
-51.9%
1M
+41.4%
1W
-2.8%
AUN
Auna SA
Peer
5Y
-41.0%
3Y
-41.0%
1Y
-30.8%
6M
-9.7%
1M
+21.7%
1W
+22.2%
CTE
Claritev Corporation
Peer
5Y
-91.9%
3Y
-37.9%
1Y
+5.5%
6M
-65.8%
1M
+53.3%
1W
+15.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
8.63
Forward P/E
2.69
PEG Ratio
0.38
P/B Ratio
0.8
P/S Ratio
0.56
EV/Revenue
1.07
EV/EBITDA
3.8
Market Cap
$414.71M

Profitability

Profit margins and return metrics

Profit Margin 7.08%
Operating Margin -15.2%
Gross Margin 49.44%
ROE 10.46%
ROA 5.33%

Growth

Revenue and earnings growth rates

Revenue Growth -23.6%
Earnings Growth N/A
Q/Q Revenue Growth -24.04%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
1.12
Moderate
Current Ratio
5.01
Strong
Quick Ratio
2.19
Excellent
Cash/Share
$3.97

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.1B
Gross Margin
41.0%
Op. Margin
-10.9%
Net Margin
-38.0%
Total Assets
$1.3B
Liabilities
$0.8B
Equity
$0.5B
Debt/Equity
1.52x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
95%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-04-30
$N/A
2026-02-26
$-0.43
-490.9% surprise
2025-10-29
$1.06
+984.2% surprise
2025-08-06
$0.16
+132.7% surprise

Healthcare Sector Comparison

Comparing EBS against 548 companies in the Healthcare sector (30 bullish, 163 neutral, 355 bearish)
P/E Ratio
8.63
This Stock
vs
77.48
Sector Avg
-88.9% (Discount)
Return on Equity (ROE)
10.46%
This Stock
vs
-89.9%
Sector Avg
-111.6% (Below Avg)
Profit Margin
7.08%
This Stock
vs
-16.4%
Sector Avg
-143.2% (Weaker)
Debt to Equity
1.12
This Stock
vs
2.71
Sector Avg
-58.8% (Less Debt)
Revenue Growth
-23.6%
This Stock
vs
126.74%
Sector Avg
-118.6% (Slower)
Current Ratio
5.01
This Stock
vs
4.53
Sector Avg
+10.6% (Better)

Similar Companies

Peer comparison within the same industry

EBS Emergent...
BEARISH
Mkt Cap
$415M
P/E
8.6
ROE
10.5%
Price
$8.03
OVID Ovid Therapeutics Inc.
NEUTRAL
Mkt Cap
$417M
P/E
-
ROE
-17.5%
Price
$2.76
 Compare with EBS
AGL agilon health, inc.
BEARISH
Mkt Cap
$411M
P/E
-
ROE
-73.3%
Price
$0.99
 Compare with EBS
AUNA Auna SA
NEUTRAL
Mkt Cap
$419M
P/E
5.8
ROE
11.4%
Price
$5.66
 Compare with EBS
CTEV Claritev Corporation
BEARISH
Mkt Cap
$404M
P/E
-
ROE
-%
Price
$23.81
 Compare with EBS

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

WILLIAMS PAUL ANTHONY
Officer
Sell
2026-04-01
4,000 shares · $33,760
FOWLER JOHN D JR
Director
Stock Award
2026-03-03
5,006 shares · $45,004
RICHARD RONALD B
Director
Sell
2025-12-05
21,984 shares · $263,077
RICHARD RONALD B
Director
Option Exercise
2025-12-05
25,748 shares · $129,255
DEGOLYER DONALD W
Director
Sell
2025-11-10
17,801 shares · $187,623
DAYAL SUJATA TYAGI
Director
Sell
2025-11-07
8,552 shares · $85,520
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-04-17

EBS filed an 8-K on April 17, 2026, likely to announce its first-quarter financial results.

DEF 14A
DEF 14A
2026-03-20

EBS filed a Definitive Proxy Statement on March 20, 2026, providing shareholders with necessary information to vote on corporate matters at the upcoming annual meeting.

8-K
8-K
2026-03-03

EBS filed an 8-K on March 3, 2026, likely to report its annual financial results for the preceding fiscal year.

10-K
10-K
2026-02-27

EBS filed its annual 10-K on February 27, 2026, which includes disclosures regarding its business operations, risk factors, and management's discussion and analysis of financial condition. Specific financial highlights and risk details were not provided in the available excerpts.

8-K
8-K
2026-02-26

EBS filed an 8-K on February 26, 2026, likely to announce its financial results for the fiscal year ended December 31, 2025.

8-K
8-K
2026-01-14
8-K
8-K
2026-01-12

EBS filed a current report on January 12, 2026, likely announcing a material corporate event or preliminary financial results.

8-K
8-K
2025-12-12
8-K
8-K
2025-11-12

EBS filed an 8-K on November 12, 2025, likely to announce its third-quarter financial results.

10-Q
10-Q
2025-10-30

EBS filed its 10-Q on October 30, 2025. While specific financial highlights were not provided in the excerpt, the filing includes a dedicated section for Risk Factors under Item 1A.

8-K
8-K
2025-10-29
8-K
8-K
2025-09-11
8-K
8-K
2025-09-05
10-Q
10-Q
2025-08-07
8-K
8-K
2025-08-06
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
NONE
2 analysts
HC Wainwright & Co.
2026-03-09
Maintains
Buy Buy
HC Wainwright & Co.
2025-12-16
reit
Buy Buy

Past News Coverage

Recent headlines mentioning EBS from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile